You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 2
  • 442-C A best-in-class HSC-derived CAR-Monocyte product with a novel CAR costimulatory domain significantly improves CAR-M activity against solid tumors

Citation Tools

Article menu

Download PDFPDF

Regular Abstracts – Part 2
Cellular Therapies
442-C A best-in-class HSC-derived CAR-Monocyte product with a novel CAR costimulatory domain significantly improves CAR-M activity against solid tumors

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Jeon K, Reynolds G, Birger A, et al
442-C A best-in-class HSC-derived CAR-Monocyte product with a novel CAR costimulatory domain significantly improves CAR-M activity against solid tumors
Journal for ImmunoTherapy of Cancer 2023;11:doi: 10.1136/jitc-2023-SITC2023.0442-C